--- title: "Mammary Carcinoma Case Study: Missy" description: After one year of FidoCure® targeted therapy, Missy showed no evidence of pulmonary metastatic disease. image: https://blog.fidocure.com/hubfs/missy.png --- [![FidoCure](https://blog.fidocure.com/hs-fs/hubfs/fidocure_logo.png?width=296&height=68&name=fidocure_logo.png "FidoCure")](https://www.fidocure.com/) - [Veterinarians](https://fidocure.com/for-veterinarians/) - [Portal Login](https://dvm.fidocure.com/) - [Veterinary Blog](https://blog.fidocure.com/fidocure-blog/tag/vet) - [Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies) - [Webinars](https://blog.fidocure.com/fidocure-blog/tag/webinars) - [Pet Parents](https://fidocure.com/pet-parents/) - [About Us](https://fidocure.com/about-us/) - [How it works](https://fidocure.com/how-it-works/) - [Find a Clinic](https://fidocure.com/find-a-clinic/) - [Contact Us](https://fidocure.com/contact-us/) [Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies) # Mammary Carcinoma Case Study: Missy [Dr. Gerry Post](https://blog.fidocure.com/fidocure-blog/author/dr-gerry-post) [Share this blog post on Twitter](https://twitter.com/intent/tweet?text=I+found+this+interesting+blog+post&url=https://blog.fidocure.com/fidocure-blog/mammary-carcinoma-case-study-missy) [Share this blog post on Facebook](http://www.facebook.com/share.php?u=https://blog.fidocure.com/fidocure-blog/mammary-carcinoma-case-study-missy) [Share this blog post on LinkedIn](http://www.linkedin.com/shareArticle?mini=true&url=https://blog.fidocure.com/fidocure-blog/mammary-carcinoma-case-study-missy) #### After one year of FidoCure®targeted therapy, Missy showed no evidence of pulmonary metastatic disease.   A case study about **mammary carcinoma.** After one year of FidoCure® targeted therapy, Missy showed no evidence of pulmonary metastatic disease. In October of 2018, **Missy Martino**, a 12 year-old spayed Chow Mix, was presented to the Pet Emergency and Specialty Center of Marin in San Rafael, CA. A mass of approximately 2.0 x 3.0 cm was palpated in the region of the first thoracic mammary gland of the right mammary chain. Thoraic radiographs were performed and **no evidence of pulmonary metastasis was noted**. Surgical excision of the mass was elected and then performed by the primary veterinarian on October 5, 2018. **Histopathology revealed** a high grade (grade 3) **mammary gland carcinoma** with approximately 20 mitotic figures in 10 HPFs. The mass was narrowly excised with neoplastic cells extending to within 4mm and 1mm of the lateral and deep margins, respectively. Subsequently, Missy's family was **referred to a veterinary oncologist**. In November 2018, a course of injectable chemotherapy doxorubicin (Adriamycin) 25mg/m2 IV once every three weeks for five treatments was initiated. At a re-staging appointment in April 2019, **a new mass was noted **on the right ventral thorax near the second mammary gland. Cytologic evaluation confirmed **recurrence of mammary neoplasia**; thoracic radiographs revealed two small pulmonary nodules and an enlarged sternal lymph node. These findings were consistent with metastatic disease. After discussion of additional treatment options, Missy's family elected to **pursue FidoCure® **genomic analysis and therapy. [Read the rest of Missy's story](https://fidocure.com/wp-content/uploads/2023/05/CaseStudy-Missy.pdf) ## Related Articles [![](https://blog.fidocure.com/hubfs/Adley.jpg)](https://blog.fidocure.com/fidocure-blog/lung-carcinoma-case-study-adley-hurwitz) [Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies) ### [Lung Carcinoma Case Study: Adley Hurwitz](https://blog.fidocure.com/fidocure-blog/lung-carcinoma-case-study-adley-hurwitz) #### After six months of FidoCure® enabled therapy, Adley showed no evidence of pulmonary mass recurrence. [Dr. Gerry Post](https://blog.fidocure.com/fidocure-blog/author/dr-gerry-post) [Read More](https://blog.fidocure.com/fidocure-blog/lung-carcinoma-case-study-adley-hurwitz) [![](https://blog.fidocure.com/hubfs/lulu.jpg)](https://blog.fidocure.com/fidocure-blog/thyroid-carcinoma-case-study-lulu) [Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies) ### [Thyroid Carcinoma Case Study: Lulu](https://blog.fidocure.com/fidocure-blog/thyroid-carcinoma-case-study-lulu) #### After more than 20 months of FidoCure® enabled treatment, Lulu has remained free from further metaseses. There has been no evidence of disease recurrence or pulmonary... [Dr. Gerry Post](https://blog.fidocure.com/fidocure-blog/author/dr-gerry-post) [Read More](https://blog.fidocure.com/fidocure-blog/thyroid-carcinoma-case-study-lulu) ![fc_portal_logo_bw](https://blog.fidocure.com/hubfs/fc_portal_logo_bw.svg) - [How it Works](https://fidocure.com/how-it-works/) - [FAQ](https://fidocure.com/faq/) - [Contact Us](https://fidocurestg.wpengine.com/contact-us/) - [For Vets](https://fidocure.com/for-veterinarians/) - [About Us](https://fidocure.com/about-us/) - [Terms of Service](https://fidocure.com/terms-of-service/) - [Blog](https://blog.fidocure.com/fidocure-blog) - [Careers](https://fidocure.com/careers/) - [Privacy Policy](https://fidocure.com/privacy-policy/) - - - - **FidoCure® is an advanced cancer-care service for dogs, developed by One Health Company**. DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy.  © Copyright 2018-2026 One Health Company, All rights reserved ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Dr. Gerry Post", "url" : "https://blog.fidocure.com/fidocure-blog/author/dr-gerry-post" }, "dateModified" : "2023-05-10T14:23:51.845Z", "datePublished" : "2023-05-04T17:40:42.000Z", "headline" : "Mammary Carcinoma Case Study: Missy", "image" : [ "https://blog.fidocure.com/hubfs/missy.png" ], "mainEntityOfPage" : { "@id" : "https://blog.fidocure.com/fidocure-blog/mammary-carcinoma-case-study-missy", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.fidocure.com/hubfs/fidocure_logo.png" }, "name" : "FidoCure" } } ```